{"id":134521,"date":"2026-08-10T03:05:09","date_gmt":"2026-08-10T03:05:09","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/134521\/"},"modified":"2026-08-10T03:05:09","modified_gmt":"2026-08-10T03:05:09","slug":"is-radnet-rdnt-undervalued-as-ai-growth-hopes-push-the-stock-higher","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/134521\/","title":{"rendered":"Is RadNet (RDNT) Undervalued As AI Growth Hopes Push The Stock Higher?"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St. <\/p>\n

Recent trading action and performance snapshot <\/p>\n

RadNet (RDNT) has drawn investor attention after recent trading, with the stock closing at US$72.39 on 4 August 2026. That closing price implies a market value of about US$5.69b. <\/p>\n

Over the past week the stock return was 13.49%, while the past month showed a 10.34% gain and the past 3 months a 29.49% gain. The 1 year total return stands at 35.65%. <\/p>\n

See our latest analysis for RadNet.<\/a> <\/p>\n

For RadNet, the recent 6.2% 1 day share price return and 13.49% 7 day share price return come on top of a 35.65% 1 year total shareholder return and a much stronger multi year total shareholder return. Taken together, these figures suggest that momentum has been building rather than fading. <\/p>\n

If you are interested in what else is moving around healthcare and AI, this is a useful moment to broaden your watchlist with 43 healthcare AI stocks<\/a> <\/p>\n

After RadNet’s sharp move higher, the real tension is between locking in exposure now or waiting for a pullback that may not come. The next step is to see what the current valuation actually implies. <\/p>\n

Most Popular Narrative: 19.3% Undervalued <\/p>\n

RadNet’s most followed valuation narrative places fair value at $89.75 per share, which sits above the recent $72.39 close and frames the current upside debate. <\/p>\n

Ongoing investments in AI-powered imaging solutions (e.g., DeepHealth, See-Mode, iCAD) are materially increasing center throughput, boosting capacity utilization, and driving more high-margin advanced procedures, directly enhancing both revenue growth and EBITDA margins as adoption scales through 2026. <\/p>\n

Read the complete narrative.<\/a> <\/p>\n

Want to see what this assumes for RadNet’s next chapter? The narrative leans on faster revenue, higher margins and a richer future profit multiple. It highlights the combination of growth, profitability and valuation that would need to align to support that fair value. <\/p>\n

The narrative uses a discount rate of 7.37% and incorporates forecasts that RadNet shifts from a current net loss of $14.2m to meaningful earnings by 2029. It also includes expectations for double digit annual revenue growth and a future valuation multiple that sits well above the broader US healthcare sector, which is part of why the implied fair value is materially higher than where the stock trades today. <\/p>\n

For investors, a key question is whether that path to stronger profits and a higher future P\/E appears realistic given RadNet’s mix of imaging centers and digital health, or whether the bar is set too high. In either case, the narrative provides a defined financial roadmap that can be compared against actual quarterly results as they are reported in the coming years. <\/p>\n

Result: Fair Value of $89.75 (UNDERVALUED) <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, RadNet’s story could be knocked off course if heavy AI and digital health spending strains cash flow, or if reimbursement and payer contract changes pressure margins. <\/p>\n

Find out about the key risks to this RadNet narrative.<\/a> <\/p>\n

Another view on RadNet’s valuation using sales multiples <\/p>\n

RadNet looks very different when you shift from the narrative fair value of $89.75 to its current sales multiple. The stock trades on a P\/S of 2.7x, which is higher than the estimated fair ratio of 1.1x and the US Healthcare industry average of 1.5x. <\/p>\n

This gap suggests investors are already paying a premium for RadNet relative to both its sector and what the fair ratio points to, which could mean less room for error if growth or margins fall short. The key question is whether you think the company can deliver enough progress to justify staying above that 1.1x level over time. <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

\"NasdaqGM:RDNT<\/a> NasdaqGM:RDNT P\/S Ratio as at Aug 2026 Next Steps <\/p>\n

With RadNet showing both enthusiasm around growth and concern around risks, it makes sense to look at the full picture yourself and move quickly. To see both sides of the argument in one place, review the 3 key rewards and 2 important warning signs<\/a> <\/p>\n

Looking for more investment ideas beyond RadNet? <\/p>\n

If RadNet has caught your attention, do not stop there. Spending a few minutes with the right stock ideas now could influence your portfolio later. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include RDNT<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":134522,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24,25,3305,109,66771,4871],"class_list":["post-134521","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-ai","tag-artificial-intelligence","tag-fair-value","tag-individual-investors","tag-radnet","tag-total-shareholder-return"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/134521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=134521"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/134521\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/134522"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=134521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=134521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=134521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}